introduction
Arterial stiffness is a term used to define the viscoelastic properties of the vessel wall and refers to arterial wall rigidity. 1 Ageing of the arterial system, progressive structural changes, disintegration and degeneration of elastin, collagen deposition, arterial wall thickening, endothelial damage and progressive arterial dilatation are all associated with arterial stiffness. 2, 3 Deterioration of coronary perfusion and left ventricular hypertrophy secondary to arterial stiffness increase morbidity and mortality. 1, 3, 4 Cardiovascular events and cardiovascular mortality increase in the early stage of chronic kidney disease (CKD). Arterial stiffness is an independent predictor of cardiovascular disease in CKD. [5] [6] [7] Increase in arterial stiffness emerges before atherosclerosis and has been evaluated as an early marker of systemic atherosclerosis. Arterial stiffness is independently associated with cardiovascular events and all-cause mortality. 4, 6 Vitamin D deficiency is quite common worldwide affecting approximately 30-50% of the global population, and measuring 25-hydroxyvitamin D (25(OH)D) is the best method for determining vitamin D deficiency due to its longer half-life. [8] [9] [10] Values of 25(OH)D above 30 ng/mL are considered normal. 8, 10, 11 Vitamin D plays a crucial role in bone and calcium metabolism. In addition, it has beneficial effects on the immune system, blood pressure regulation, vascular endothelial function, and body growth and development. 9, 10, 12 Previous studies have demonstrated the association between 25(OH)D deficiency and increased arterial stiffness in chronic diseases such as lupus, diabetes, hyperparathyroidism, and kidney disease. [13] [14] [15] Pulse wave velocity (PWV) and augmentation index normalized with 75/min heart rate (Alx@75) are considered to be gold standard index for arterial stiffness.
1,3,6 Al Mheid et al. 16 demonstrated that 25(OH)D levels negatively correlated with PWV and Alx in healthy subjects, and reported that vitamin D deficiency increased arterial stiffness effecting by vascular dysfunction.
In our study, we aimed to evaluate the prevalence of 25(OH)D deficiency and the relationship between 25(OH) D and PWV, and Alx@75 in patients with stage 3B-5 CKD.
Method
One hundred and one (101) patients over 18 years of age with stage 3B-5 CKD not on dialysis, diagnosed by using the specified in the KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease 17 were recruited. Patients were excluded from the study if they were known to have coronary artery disease, heart failure, valvular heart disease, metal valves, stents, metal prosthesis, peripheral artery disease, malignancy, active autoimmune disorders, recent acute coronary syndrome (within the last three months), or if already on vitamin D supplementation. The study was conducted during winter (December through March) throughout the years 2012-2015. Our study was conducted in accordance with the Helsinki declaration, and was approved by the local ethics committee of clinical research (decision number 2016/870, dated 12.05.2016). The patients were informed about the nature of the study, and informed consent was obtained from all participants before entering the study.
All patients underwent a physical examination that included height and weight measurements, age, sex, and etiology of CKD as recorded in the medical chart of each patient. Body mass index was calculated by dividing body weight (kg) by the square of the body height (m 2 ). 
Study group

Arterial stiffness measurement
Arterial stiffness measurements were performed using the oscillometric method. After 15 minutes of rest, measurements were performed with a single-cuff arteriograph device (Mobil-O-Graph PWA, a model pulse wave analysis device, I.E.M. GmbH, Stolberg, Germany). An appropriate blood pressure cuff was placed on the brachial artery trace of the upper arm. The arteriograph device performed three consecutive measurements automatically at 30-sec intervals. The arteriograph measures the blood pressure in the upper arm; then, the device inflates the pressure cuff to 35 mmHg above the systolic blood pressure. This enables detection of fluctuations in brachial artery pressure. A tonometric sensor amplifies the fluctuations and transmits them to the arteriograph. The device software program decomposes early and late systolic and diastolic waves. Pulse wave velocity, pulse pressure, central systolic -diastolic pressure calculated by the central pressure changes, early (direct, P1), late (backward, P2) systolic and diastolic waves. Augmentation pressure is the difference between the first and second systolic peak, and Alx is calculated as the proportion of augmentation pressure to pulse pressure. Augmentation index was normalized to a heart rate of 75 bpm (AIx@75) for comparison for different heart rates.
3,18
Statistical analysis Statistical analyses were carried out using the Statistical Package for Social Sciences for Windows, version 17 (SPSS Inc., Chicago, IL, USA). Kolmogorov-Smirnov test was used to determine the normality of the variables' distribu- 11 .4%, respectively. In group I, 50% of the diabetic patients were using insulin and 50% were using oral antidiabetic drugs, and in group II 66.7% of the diabetic patients were using insulin and 33.3% were using oral antidiabetic drugs. In all, 64.5% of group I and 52.9% of group II were using a single antihypertensive. Use of antihypertensive drugs is shown in Table 1 . Mean Alx@75 value was significantly higher in group II (28.6±10.8% vs. 23.3±13.5%, p=0.038). The PWV values in group I and group II were 8.0±1.7 and 8.2±1.4 m/s, respectively, but the difference was not significant (Figure 2 ). Serum albumin (p<0.001), hemoglobin (p=0.005), calcium (p=0.041), and eGFR (p=0.041) were significantly lower in group II. Mean age, BMI, parathyroid hormone and uric acid were similar in both groups. Twenty four-hour proteinuria was significantly higher in group II. Group II had a significantly higher ratio of female patients; 82% of all the females in the study were in group II (p=0.006). Demographic features of the groups are shown in Table 1 . There was a significant gender difference in mean 25(OH) D levels: 12.2±7.8 ng/mL among female patients and 16.0±7.7 ng/mL for male patients (p=0.016).
In an analysis of all patients, 25(OH)D level was inversely correlated with Alx@75 (p=0.002, r=-0.307), augmentation pressure (p=0.030, r=-0.216), parathyroid hormone (p=0.014, r=-0.255), proteinuria (p=0.018, r=-0.252) and BMI (p=0.042, r=-0.203), while 25(OH)D level positively correlated with albumin (p<0.001, r=0.394), hemoglobin (p=0.031, r=0.215), eGFR (p=0.016, r=0.239), calcium (p=0.014, r=0.243) and transferrin (p=0.040, r=0.344). To identify independent determinants of 25(OH)D, a multivariate regression analysis was performed on the parameters that were found to be correlated with 25(OH)D. In backward multiple regression analysis, 25(OH)D was independently associated with Alx@75 (beta=-0.469, p=0.001) and albumin (beta=0.447, p=0.002).
discussion
Vitamin D deficiency is a worldwide problem. Studies conducted with healthy subjects found 25(OH)D deficiency at rates of 42% in America, 19 40.4% in Europe 20 and 60% in Eastern countries. 21 A meta-analysis showed that 88% of healthy individuals have 25(OH)D lower than 30 ng/mL. 22 The prevalence of vitamin D deficiency in CKD patients not on dialysis has been reported between 21.5-58.3%, 15, [23] [24] [25] and mean 25(OH)D was determined as 18±8 ng/mL. 15 In the present study, the prevalence of vitamin D deficiency was 69.4%; only 5.9% of patients had 25(OH)D levels higher than 30 ng/mL, and mean 25(OH)D was 14.1±7.9 ng/ mL. Vitamin D deficiency is common in CKD, which has been attributed to many factors such as reduced sun exposure, decreased vitamin D-binding protein, proteinuria, reduced dietary intake, advanced age, malabsorption, and down-regulation of megalin levels. 8, 15, 26, 27 In Middle Eastern and South Asian developing countries, levels of 25(OH)D < 10 ng/mL were reported in 50% of the population and higher risk was noted among females. 28 Of females aged 24-77 years living in Rabat, 91% had lower than 30 ng/mL 25(OH)D, and female sex was considered a predictor of 25(OH)D deficiency. 29 Reports of 25(OH)D deficiency in females tend to be particularly common in the Asia/Pacific and Middle East/Africa regions, possibly due to women wearing a more covered clothing style compared to females in other parts of the world. 22 Vitamin D deficiency in females was significantly higher in our study, in accordance with previous studies. 23, 28 This may be attributable to the covered clothing style worn by Turkish females due to cultural factors.
It has been shown that PWV and Alx are negatively associated with 25(OH)D in healthy subjects, postmenopausal women, and patients with diabetes mellitus, peripheral arterial disease, rheumatologic diseases and kidney disease. [13] [14] [15] [16] 30, 31 Brachial-ankle PWV was found to be significantly lower in CKD patients with 25(OH)D deficiency. Cholecalciferol supplementation of 40,000 IU every week for 8 weeks had no significant impact on both PWV and Alx@75 in CKD patients as previously shown. 33 In another study, Chitalia et al. 32 administered two doses of 300,000 IU cholecalciferol at baseline and 8-weeks to CKD stage 3-4 patients, PWV decreased from 7.9±1.9 to 7.7±2.2 m/s and Alx decreased from 22±16% to 18±20% at week 16. However, they concluded that PWV and Alx tended to improve but did not reach statistical significance.
In our study, Alx@75, a marker of arterial stiffness, was higher among patients with 25 of arterial stiffness in CKD. Vitamin D has a beneficial impact on the renin-angiotensin system, endothelium mediated vasodilatation, insulin resistance, inhibition of vascular smooth muscle proliferation, macrophage activation and cytokine production. 10, 12, 34 Vascular smooth muscle cell proliferation, the renin-angiotensin-aldosterone system and macrophage invasion of blood vessel walls are activated by vitamin D deficiency. In addition, parathyroid hormone secretion and inflammatory cytokine gene expression are increased. All these pathological processes result in decreased vascular compliance, increased vascular calcification and inflammation, which may contribute to the development of arterial stiffnesss. 3, 15, 16, 27 Vitamin D deficiency is associated with cardiovascular disease, all-cause mortality, morbidity, poor clinical outcomes and rapid decline of eGFR in patients with CKD. 25, 34, 35 Our study has some limitations. First, 25(OH)D tended to decrease as PWV and CKD stage increased. However, we were unable to definitively confirm the association of 25(OH)D deficiency with PWV and CKD stage due to a relatively small cohort. Secondly, this was a cross-sectional case-control study; therefore, we could not evaluate the effect of vitamin D treatment on arterial stiffness, CKD progression or mortality. 
